Antineoplastic agents, 301. An investigation of the amaryllidaceae genus hymenocallis

George Pettit, George R. Pettit, Grazyna Groszek, Ralph A. Backhaus, Dennis L. Doubek, Roland J. Barr, Alan W. Meerow

Research output: Contribution to journalArticle

55 Scopus citations

Abstract

Seven species (and one cultivated variety) of Hymenocallis (Amaryllidaceae) and the related Pancratium maritima, representing a broad geographical selection, were investigated as sources of pancratistatin [1] now undergoing preclinical development as an anticancer agent. Pancratistatin [1] was found to be a constituent of H. speciosa (Singapore), H. variegated (Singapore), H. pedalis (Seychelles), H. expansa (Bermuda), H. sonoranensis (Mexico), and P. maritimum (Israel). Only two species of Hymenocallis failed to yield one or more of the related cell-growth inhibitory isocarbostyrils such as narciclasine [3a], 7-deoxynarciclasine [3b], and 7-deoxy-trans-dihydronarciclasine [2].

Original languageEnglish (US)
Pages (from-to)756-759
Number of pages4
JournalJournal of Natural Products
Volume58
Issue number5
DOIs
StatePublished - May 1995

ASJC Scopus subject areas

  • Analytical Chemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine
  • Organic Chemistry

Fingerprint Dive into the research topics of 'Antineoplastic agents, 301. An investigation of the amaryllidaceae genus hymenocallis'. Together they form a unique fingerprint.

  • Cite this

    Pettit, G., Pettit, G. R., Groszek, G., Backhaus, R. A., Doubek, D. L., Barr, R. J., & Meerow, A. W. (1995). Antineoplastic agents, 301. An investigation of the amaryllidaceae genus hymenocallis. Journal of Natural Products, 58(5), 756-759. https://doi.org/10.1021/np50119a017